Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease

Movement Disorders

Volumn 25, Issue SUPPL. 1, 2010, Pages

  Carta, Manolo ^a   Carlsson, Thomas ^a   Muñoz, Ana ^a   Kirik, Deniz ^a   Björklund, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

5 HT1A receptor agonist; 5 HT1B receptor agonist; Dyskinesia; Graft induced dyskinesia; L dopa; Serotonin

Indexed keywords

5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; 8 OHDPAT; BUSPIRONE; DOPAMINE; LEVODOPA; SARIZOTAN; SEROTONIN 1A AGONIST; SEROTONIN 1B AGONIST; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; SEROTONIN;

ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOSE RESPONSE; DRUG MECHANISM; DYSKINESIA; GRAFT RECIPIENT; HUMAN; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SEROTONIN SYNDROME; SEROTONINERGIC NERVE CELL; ANIMAL; DISEASE MODEL; DRUG EFFECT; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; TRANSPLANTATION;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DYSKINESIAS; HUMANS; LEVODOPA; NEURONS; PARKINSON DISEASE; SEROTONIN; TRANSPLANTS;

EID: 77953394342     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22792     Document Type: Article

References (60)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-458.
2. Cragg SJ, Rice ME. DAncing past the DAT at a DA synapse. Trends Neurosci 2004; 27: 270-277.
3. Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM. Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. J Neurochem 2003; 87: 1284-1295.
4. Arai R, Karasawa N, Geffard M, Nagatsu I. L-dopa is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 1995; 195: 195-198.
5. Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-dopa in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res 1994; 667: 295-299.
6. Arai R, Karasawa N, Nagatsu I. Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res 1996; 706: 177-179.
7. Hollister AS, Breese GR, Mueller RA. Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity. J Pharmacol Exp Ther 1979; 208: 37-43.
8. Lavoie B, Parent A. Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol 1990; 299: 1-16.
9. Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered L-dopa. Brain Res 2005; 1046: 230-233.
10. Ng KY, Chase TN, Colburn RW, Kopin IJ. L-Dopa-induced release of cerebral monoamines. Science 1970; 170: 76-77.
11. Ng KY, Colburn RW, Kopin IJ. Effects of L-dopa on efflux of cerebral monoamines from synaptosomes. Nature 1971; 230: 331-332.
12. Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol 2002; 9( Suppl 3): 1-6.
13. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. Role of serotonergic neurons in L-dopa-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999; 10: 631-634.
14. Kannari K, Tanaka H, Maeda T, Tomiyama M, Suda T, Matsunaga M. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-dopa administration in rats with nigrostriatal denervation. J Neurochem 2000; 74: 263-269.
15. Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D. Serotonin neuron transplants exacerbate L-dopa-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 2007; 27: 8011-8022.
16. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-dopa-induced dyskinesia in parkinsonian rats. Brain 2007; 130(Part 7): 1819-1833.
17. Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-dopa in the striatum with nigrostriatal denervation. J Neurochem 2001; 76: 1346-1353.
18. Munoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-dopa-induced dyskinesia. Brain 2008; 131(Part 12): 3380-3394.
19. Lopez-Real A, Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL. Localization and functional significance of striatal neurons immunoreactive to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models. Brain Res 2003; 969: 135-146.
20. Melamed E, Hefti F, Pettibone DJ, Liebman J, Wurtman RJ. Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism. Neurology 1981; 31: 651-655.
21. Mura A, Jackson D, Manley MS, Young SJ, Groves PM. Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-dopa to dopamine. Brain Res 1995; 704: 51-60.
22. de la Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 2004; 127(Part 4): 888-899.
23. Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin Neuropharmacol 2004; 27: 245-256.
24. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000; 55( 11 Suppl 4): S72-S77; discussion S78-S81.
25. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000; 23( Suppl 10): S117-S126.
26. Chalmers DT, Watson SJ. Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain-a combined in situ hybridisation/in vitro receptor autoradiographic study. Brain Res 1991; 561: 51-60.
27. Riad M, Garcia S, Watkins KC, et al. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol 2000; 417: 181-194.
28. Adell A, Celada P, Artigas F. The role of 5-HT1B receptors in the regulation of serotonin cell firing and release in the rat brain. J Neurochem 2001; 79: 172-182.
29. Knobelman DA, Kung HF, Lucki I. Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors. J Pharmacol Exp Ther 2000; 292: 1111-1117.
30. Sari Y, Miquel MC, Brisorgueil MJ, et al. Cellular and subcellular localization of 5-hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies. Neuroscience 1999; 88: 899-915.
31. Sprouse JS, Aghajanian GK. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse 1987; 1: 3-9.
32. Ceci A, Baschirotto A, Borsini F. The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex. Neuropharmacology 1994; 33: 709-713.
33. Hajos M, Hajos-Korcsok E, Sharp T. Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol 1999; 126: 1741-1750.
34. Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P. In MPTP treated primates, the selective 5-HT1a agonist (R)-(+)-8-hydroxy-DPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J Pharmacol Exp Ther 2006; 319: 1225-1234.
35. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001; 57: 1829-1834.
36. Gregoire L, Samadi P, Graham J, Bedard PJ, Bartoszyk GD, Di Paolo T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-dopa in parkinsonian monkeys. Parkinsonism Relat Disord 2009; 15: 445-452.
37. Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 2009; 63: 610-620.
38. Antonelli T, Fuxe K, Tomasini MC, et al. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 2005; 58: 193-199.
39. Dupre KB, Eskow KL, Barnum CJ, Bishop C. Striatal 5-HT(1A) receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008; 55: 1321-1328.
40. Dupre KB, Eskow KL, Negron G, Bishop C. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 2007; 1158: 135-143.
41. Mignon LJ, Wolf WA. 8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport 2005; 16: 699-703.
42. Muñoz A, Carlsson T, Tronci E, Kirik D, Björklund A, Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol 2009; 219: 298-307.
43. Zhang X, Andren PE, Greengard P, Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-dopa treatment of an animal model of Parkinsonism. Proc Natl Acad Sci USA 2008; 105: 2163-2168.
44. Carey RJ, Depalma G, Damianopoulos E, Muller CP, Huston JP. The 5-HT1A receptor and behavioral stimulation in the rat: effects of 8-OHDPAT on spontaneous and cocaine-induced behavior. Psychopharmacology (Berl) 2004; 177: 46-54.
45. Goodwin GM, De Souza RJ, Wood AJ, Green AR. The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism. Psychopharmacology (Berl) 1986; 90: 488-493.
46. Yamada J, Sugimoto Y, Horisaka K. The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Eur J Pharmacol 1988; 154: 299-304.
47. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-719.
48. Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002; 5: 627-628.
49. Carlsson T, Winkler C, Lundblad M, Cenci MA, Bjorklund A, Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol Dis 2006; 21: 657-668.
50. Ma Y, Feigin A, Dhawan V, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002; 52: 628-634.
51. Maries E, Kordower JH, Chu Y, et al. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis 2006; 21: 165-180.
52. Carlsson T, Carta M, Munoz A, et al. Impact of grafted serotonin and dopamine neurons on development of L-dopa-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009; 132(Part 2): 319-335.
53. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994; 17: 73-82.
54. Kleedorfer B, Lees AJ, Stern GM. Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 1991; 54: 376-377.
55. Olanow CW, Damier P, Goetz CG, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004; 27: 58-62.
56. Bara-Jimenez W, Bibbiani F, Morris MJ, et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005; 20: 932-936.
57. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007; 22: 179-186.
58. Casanovas JM, Hervas I, Artigas F. Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex. Neuroreport 1999; 10: 1441-1445.
59. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71: 533-554.
60. Smith LM, Peroutka SJ. Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem Behav 1986; 24: 1513-1519.